Lonza Group AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LZAGY | 3759.HK | BIIB | 301080.SZ | 4583.T | ROIV | |
|---|---|---|---|---|---|---|
| Market cap | 57.95B | 55.85B | 37.61B | 16.17B | 6.73B | 27.61B |
| P/E (TTM) | 42.9 | 27.4 | 110.2 | 83.1 | — | — |
| Forward P/E | 29.6 | 17.2 | 15.6 | — | -2.8 | -27.5 |
| Price/book | 5.8 | 2.8 | 2.0 | 5.9 | 4.2 | 6.5 |
| Dividend yield | 0.78% | 0.78% | — | 0.63% | — | — |
| 1-year change | +19.09% | +19.72% | +62.35% | +56.35% | −35.11% | +85.85% |
| Today | +2.82% | +3.47% | +2.22% | +1.77% | −2.35% | +6.08% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 20 min.
Latest news
All LZAGY news ›Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites
Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would…
More from 1 other outlet
Merck to divest CDMO business across five US sites to Lonza
Merck has signed a definitive agreement to sell its CDMO business to Lonza for a mid-triple-digit million-euro sum, with the transaction expected to complete in mid-2027. Merck has agreed to divest its contract development and…
More from 1 other outlet
Lonza buys Merck CDMO in Germany to double U.S. footprint as Korea rivals race
Deal adds five U.S. sites as Samsung Biologics and Celltrion accelerate global capacity grabs Lonza, the world's No. 1 biopharmaceutical CDMO company, is expanding its U.S. production foothold and bulking up. Korean corporations Samsung…
Lonza to Buy Five Merck Drug-Manufacturing Plants, Including Carlsbad Site
One asset is explicitly staying put. BioReliance Contract Testing Services is not included in the transaction and will remain an important part of Merck's Life Science portfolio, the company said in its statement. Until the sale closes,…
Lonza to buy Merck KGaA’s contract manufacturing business
The Swiss contract development and manufacturing organization (CDMO) Lonza has agreed to buy the drug services business of Germany’s Merck KGaA. The purchase will give Lonza five new manufacturing sites in the US, doubling the company’s US…
More from 1 other outlet
Lonza to offload capsule and health ingredients biz to Lone Star in $3bn transaction
The move marks the culmination of Lonza’s transformation and positions the company to focus exclusively on its CDMO operations. Swiss contract development and manufacturing organization (CDMO) Lonza has announced the divestment of its…
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
Lonza has struck a deal to buy five U.S. manufacturing plants from Merck KGaA at a valuation ranging in the low- to mid-triple-digit millions in Swiss francs. Responding to an analyst on a conference call Tuesday, Lonza CEO Wolfgang…
Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding…
Lonza to Buy Merck KGaA's US CDMO Sites, Lifting American Footprint to Nine Plants
Lonza Group AG has agreed to acquire the contract development and manufacturing organization (CDMO) business of Germany's Merck KGaA, a deal that will take the Swiss contractor's U.S. production network from four sites to nine and add…
Lonza to acquire five US manufacturing sites from Merck KGaA
The deal would expand Lonza’s US presence from four to nine sites and bring 1,100 employees into its global workforce. Lonza has entered a definitive agreement to purchase five US contract development and manufacturing organisation (CDMO)…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com11
- manufacturingchemist.com3
- openpr.com3
- seekingalpha.com3
- biopharminternational.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 59 articles, not a forecast.